Elisabeth E Fransen van de Putte1, Laura S Mertens2, Richard P Meijer2,3, Michiel S van der Heijden4, Axel Bex2, Henk G van der Poel2, J Martijn Kerst4, Andries M Bergman4, Simon Horenblas2, Bas W G van Rhijn2. 1. Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. e.fransen@nki.nl. 2. Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. 3. Department of Urology, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Abstract
PURPOSE: To investigate the efficacy and safety of neoadjuvant induction dose-dense MVAC (dd-MVAC) for muscle invasive bladder cancer (MIBC). Results of the 2-week-per-cycle regimen were compared with classic MVAC (4 weeks per cycle) and gemcitabine/cisplatin (GC, 3 weeks per cycle). METHODS: We included 166 patients with non-organ-confined MIBC, who received neoadjuvant induction dd-MVAC (80), classic MVAC (35), or GC (51) between 1990 and 2014. Complete pathological response (pCR) was defined as no evidence of residual tumor in cystectomy and lymphadenectomy specimens (ypT0N0). pCR and toxicity rates were compared among regimens. RESULTS: pCR was found in 29% of dd-MVAC-treated patients, which was not significantly different from classic MVAC (20%, p = 0.366) and GC (32%, p = 0.845). Grade 3-4 toxicity rates related to dd-MVAC and GC (44%) were similar (p = 0.202), whereas the toxicity rate for classic MVAC (55%) was significantly higher than for dd-MVAC (32%) uncorrected (p = 0.026) and corrected for patient and tumor characteristics (OR 2.84, p = 0.037). CONCLUSIONS: Neoadjuvant induction dd-MVAC resulted in pathological response rates similar to classic MVAC and GC treatment in patients with non-organ-confined MIBC. The shorter cycle duration compared with classic MVAC and GC and the significantly lower toxicity rate compared with classic MVAC indicate that dd-MVAC should be the preferred option for neoadjuvant induction treatment.
PURPOSE: To investigate the efficacy and safety of neoadjuvant induction dose-dense MVAC (dd-MVAC) for muscle invasive bladder cancer (MIBC). Results of the 2-week-per-cycle regimen were compared with classic MVAC (4 weeks per cycle) and gemcitabine/cisplatin (GC, 3 weeks per cycle). METHODS: We included 166 patients with non-organ-confined MIBC, who received neoadjuvant induction dd-MVAC (80), classic MVAC (35), or GC (51) between 1990 and 2014. Complete pathological response (pCR) was defined as no evidence of residual tumor in cystectomy and lymphadenectomy specimens (ypT0N0). pCR and toxicity rates were compared among regimens. RESULTS: pCR was found in 29% of dd-MVAC-treated patients, which was not significantly different from classic MVAC (20%, p = 0.366) and GC (32%, p = 0.845). Grade 3-4 toxicity rates related to dd-MVAC and GC (44%) were similar (p = 0.202), whereas the toxicity rate for classic MVAC (55%) was significantly higher than for dd-MVAC (32%) uncorrected (p = 0.026) and corrected for patient and tumor characteristics (OR 2.84, p = 0.037). CONCLUSIONS: Neoadjuvant induction dd-MVAC resulted in pathological response rates similar to classic MVAC and GC treatment in patients with non-organ-confined MIBC. The shorter cycle duration compared with classic MVAC and GC and the significantly lower toxicity rate compared with classic MVAC indicate that dd-MVAC should be the preferred option for neoadjuvant induction treatment.
Authors: Richard P Meijer; Laura S Mertens; Bas W van Rhijn; Axel Bex; Henk G van der Poel; Wim Meinhardt; J Martijn Kerst; Andre M Bergman; Annemarie Fioole-Bruining; Erik van Werkhoven; Simon Horenblas Journal: Urology Date: 2013-11-15 Impact factor: 2.649
Authors: Matthew D Galsky; Noah M Hahn; Jonathan Rosenberg; Guru Sonpavde; Thomas Hutson; William K Oh; Robert Dreicer; Nicholas Vogelzang; Cora Sternberg; Dean F Bajorin; Joaquim Bellmunt Journal: Lancet Oncol Date: 2011-03 Impact factor: 41.316
Authors: R P Meijer; J A Nieuwenhuijzen; W Meinhardt; A Bex; H G van der Poel; B W van Rhijn; J M Kerst; A M Bergman; E van Werkhoven; S Horenblas Journal: Eur J Surg Oncol Date: 2013-01-31 Impact factor: 4.424
Authors: Homayoun Zargar; Patrick N Espiritu; Adrian S Fairey; Laura S Mertens; Colin P Dinney; Maria C Mir; Laura-Maria Krabbe; Michael S Cookson; Niels-Erik Jacobsen; Nilay M Gandhi; Joshua Griffin; Jeffrey S Montgomery; Nikhil Vasdev; Evan Y Yu; David Youssef; Evanguelos Xylinas; Nicholas J Campain; Wassim Kassouf; Marc A Dall'Era; Jo-An Seah; Cesar E Ercole; Simon Horenblas; Srikala S Sridhar; John S McGrath; Jonathan Aning; Shahrokh F Shariat; Jonathan L Wright; Andrew C Thorpe; Todd M Morgan; Jeff M Holzbeierlein; Trinity J Bivalacqua; Scott North; Daniel A Barocas; Yair Lotan; Jorge A Garcia; Andrew J Stephenson; Jay B Shah; Bas W van Rhijn; Siamak Daneshmand; Philippe E Spiess; Peter C Black Journal: Eur Urol Date: 2014-09-23 Impact factor: 20.096
Authors: J A Nieuwenhuijzen; A Bex; W Meinhardt; J M Kerst; J H Schornagel; H VAN Tinteren; S Horenblas Journal: J Urol Date: 2005-07 Impact factor: 7.450
Authors: C N Sternberg; P H de Mulder; A T van Oosterom; S D Fossa; D Giannarelli; J R Soedirman Journal: Ann Oncol Date: 1993-05 Impact factor: 32.976
Authors: Elizabeth R Plimack; Jean H Hoffman-Censits; Rosalia Viterbo; Edouard J Trabulsi; Eric A Ross; Richard E Greenberg; David Y T Chen; Costas D Lallas; Yu-Ning Wong; Jianqing Lin; Alexander Kutikov; Efrat Dotan; Timothy A Brennan; Norma Palma; Essel Dulaimi; Reza Mehrazin; Stephen A Boorjian; William Kevin Kelly; Robert G Uzzo; Gary R Hudes Journal: J Clin Oncol Date: 2014-05-12 Impact factor: 44.544
Authors: Luca Boeri; Matteo Soligo; Igor Frank; Stephen A Boorjian; R Houston Thompson; Matthew Tollefson; Robert Tarrel; Fernando J Quevedo; John C Cheville; R Jeffrey Karnes Journal: World J Urol Date: 2019-02-25 Impact factor: 4.226
Authors: Sean A Fletcher; Sabrina S Harmouch; Marieke J Krimphove; Alexander P Cole; Sebastian Berg; Philipp Gild; Mark A Preston; Guru P Sonpavde; Adam S Kibel; Maxine Sun; Toni K Choueiri; Quoc-Dien Trinh Journal: World J Urol Date: 2018-06-14 Impact factor: 4.226
Authors: Chelsea K Osterman; Dilip S Babu; Daniel M Geynisman; Bianca Lewis; Robert A Somer; Arjun V Balar; Matthew R Zibelman; Elizabeth A Guancial; Gianna Antinori; Shun Yu; Vivek Narayan; Thomas J Guzzo; Elizabeth R Plimack; David J Vaughn; Chunkit Fung; Ronac Mamtani Journal: Oncologist Date: 2019-02-06
Authors: Thenappan Chandrasekar; Neil Pugashetti; Blythe Durbin-Johnson; Marc A Dall'Era; Christopher P Evans; Ralph W deVere White; Stanley A Yap Journal: Bladder Cancer Date: 2016-10-27